

# European Journal of Clinical Investigation

THE JOURNAL OF THE EUROPEAN SOCIETY FOR  
CLINICAL INVESTIGATION

## Officers and members of the ESCI council 1993/1994:

President	J.F. Martin	(London)
Vice-Presidents	M. Radomski G. A. Spinaz	(Beckenham) (Zurich)
Honorary Secretary-Treasurer*	H. A. Koomans	(Utrecht)
Honorary Secretary-Treasurer Elect	T W A de Bruin	(Utrecht)
Councillors	G. Friedlander L. Galanti C. Gisinger S. Keiding M. de Oya A. E. Pontiroli H. M. Schulte A. J. Verhoeven, ex officio	(Paris) (Yvoir) (Vienna) (Aarhus) (Madrid) (Milan) (Hamburg) (Amsterdam)
Secretary Central Office	J. C. du Mosch-Poot	(Utrecht)
Address Central Office	Bolongnalaan 40 3584 CJ Utrecht, The Netherlands telephone No. + 31 (0) 30 50 87 87 telex No. + 31 (0) 30 51 57 24	

## European Journal of Clinical Investigation

Editors-in-Chief	A. M. McGregor A L W F Eddleston J. Moxham	(all London)
Editorial address	Editorial Office European Journal of Clinical Investigation (EJCI) Dept. of Medicine King's College School of Medicine & Dentistry Bessemer Road London SE5 9PJ, United Kingdom	

# TABLE OF CONTENTS

## Abstracts 28th Annual Scientific Meeting ESCI, Toledo 1994

Abstract  
Number

### SUBSPECIALTY POSTER SESSIONS

1 - 29	Cardiovascular Medicine
30 - 45	Diabetes/Metabolism
46 - 72	Endocrinology
73 - 99	Gastroenterology/Liver
100 - 111	Haematology/Oncology
112 - 126	Hypertension
127 - 144	Nephrology
145 - 148	Respiratory Medicine
149 - 152	Rheumatology

### WORKSHOPS

153 - 239	1. Phagocytes.
240 - 243	2. Growth hormone.
244 - 256	3. Nitric oxide.
257 - 260	4. Cytokines.
261 - 288	5. Diabetic angiopathy.
289 - 311	6. Oncogenes.
312 - 315	7. IGF-1
316 - 337	8. Prevention of atherosclerosis.
338 - 340	9. Vascular SMC proliferation.
341 - 348	10. Endothelin.
349 - 355	11. Body composition.

# 28TH ANNUAL SCIENTIFIC MEETING

## LOCAL ORGANIZING COMMITTEE

*A. Gómez-Pan*

*J. J. Díez*

Servicio de Endocrinología y Nutrición

"Hospital La Paz"

P.º de la Castellana, 261

E-28046 MADRID - SPAIN

*M. D. Rodríguez Arnao*

Sección Endocrinología Pediátrica

"Hospital Gregorio Marañón"

E-28007 MADRID - SPAIN

## ABSTRACT AND INDEX

TABLE OF CONTENTS .....	page A1
ABSTRACTS .....	page A3
AUTHOR INDEX .....	page A63

**INHIBITION OF CELL PROLIFERATION IN CULTURED GRAVES' RETROOCULAR FIBROBLASTS USING ANTISENSE OLIGONUCLEOTIDES TARGETING THE C-MYC PROTOONCOGENE.** Armin E. Heufelder, Rebecca S. Bahn\*, Onno E. Janssen, and Peter C. Scriba. Molecular Thyroid Research Group, Medizinische Klinik, Klinikum Innenstadt der Ludwig-Maximilians-Universität, München, Germany, and Div. of Endocrinology\*, Mayo Clinic, Rochester, USA.

Alterations of the connective tissue compartment within the orbit play a central role in the evolution of Graves' ophthalmopathy (GO). The enhanced proliferative and metabolic activities of retroocular fibroblasts in GO are thought to result, at least in part, from paracrine and autocrine signals delivered both by infiltrating T cells and residential cells. Although inhibition of effector cell functions may have therapeutic implications, the signal transduction pathways involved have not been determined. Thus, using a panel of oligomers complementary to the translation initiation region of the human proto-oncogene c-myc, we have studied the effects of an antisense approach on these cellular functions. Antisense 16-mer phosphorothioate oligodeoxynucleotides (S-ODN) concentrations of 1-12  $\mu$ M markedly reduced the proliferative capacity of cultured Graves' retroocular fibroblasts compared to cells treated with sense or randomized oligomers of equal length and GC content (each  $p < 0.001$ ). Inhibition of cell proliferation, as determined by a non-radioactive cell proliferation assay, was 78% - 96% at 24 h with significant inhibition of 58% - 87% maintained through 96 h of cell culture. No cell cytotoxicity or changes in cell viability were observed at these concentrations. In addition, stimulation of cell proliferation by IL-1 $\alpha$  (10 U/ml) and PDGF (1 ng/ml) in retroocular fibroblasts was also markedly inhibited by these anti-c-myc S-ODN (91% and 94% at 24 h, 66% and 74% at 96 h, respectively). Further, c-myc antisense oligomers were capable of diminishing glycosaminoglycan (GAG) synthesis by Graves' retroocular fibroblasts both at baseline ( $p < 0.01$ ) and following stimulation with IL-1 $\alpha$  (10 U/ml;  $p < 0.001$ ) and TGF $\beta$  (10 ng/ml;  $p < 0.001$ ). In conclusion, activation of the c-myc gene may play an important role in Graves' retroocular fibroblast proliferation and GAG synthesis. The inhibitory effects of c-myc antisense S-ODN on the proliferative and metabolic activity of these cells provides a strong rationale to further study the effects of antisense strategies targeting the c-myc proto-oncogene. Loss of function analysis using antisense oligonucleotides for the suppression of oncogenes or overexpressed growth factors may be a valuable tool for studying gene functions of potential relevance to the pathogenesis of GO.

Supported by Deutsche Forschungsgemeinschaft (He 1485/3-1).